FDA Clears Way for Denovo to Launch Phase 3 Trial of DB102 for DLBCL Patients in US
News
The U.S. Food and Drug Administration (FDA) has given Denovo Biopharma the green light to advance its investigational drug DB102 into a Phase 3 clinical trial for diffuse large B-cell lymphoma ... Read more